TY - JOUR
T1 - Association between ex vivo thrombogenicity and ischemic outcome in off-pump coronary surgery
AU - Suh, Sungmin
AU - Soh, Sarah
AU - Song, Jong Wook
AU - Kwang-Sub, Kim
AU - Kwak, Young Lan
AU - Shim, Jae Kwang
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Background: Increased thrombogenicity prohibits favorable ischemic outcomes in coronary artery disease. This study investigated the association between increased maximal amplitude (MA) on thromboelastography (TEG), which reflects high platelet-fibrin clot strength, and 1-year major adverse cardiovascular events (MACE) in patients who underwent isolated multi-vessel off-pump coronary artery bypass surgery (OPCAB). Patients and Methods: Data from 657 patients were retrospectively analyzed. TEG was performed post-anesthesia induction. MACE was defined as cardiovascular death, repeat revascularization, myocardial infarction, stroke, or rehospitalization due to heart failure. Patients were analyzed by tertiles of MA (mm). Logistic regression analyzed the association between 1-year MACE and MA. Results: The incidence of MACE increased with MA tertiles (1st: [<65.0]: 4.6%; 2nd [65.0–70.3]: 9.3%; 3rd [≥70.3]: 13%; p = 0.013). Logistic regression adjusted for known risk factors for MACE revealed an increased risk of MACE with higher MA tertiles (odds ratio [OR]: 1.99 [95% confidence interval {CI}: 0.92–4.55], p = 0.089 for the 2nd tertile; OR 2.78 [95% CI: 1.32–6.28], p = 0.010 for the 3rd tertile). A restricted cubic spline model revealed a linear relationship between MA and 1-year MACE. A 10-mm increase in MA was associated with a two-fold increase in the risk of 1-year MACE. The optimal MA cutoff for predicting MACE was 69.6 (normal range: 50.6–69.4). Conclusions: Increased thrombogenicity, reflected by elevated MA values, was linearly associated with the occurrence of 1-year MACE, highlighting the need for TEG screening and more aggressive, individualized perioperative anticoagulation management in selected patients with increased MA requiring OPCAB.
AB - Background: Increased thrombogenicity prohibits favorable ischemic outcomes in coronary artery disease. This study investigated the association between increased maximal amplitude (MA) on thromboelastography (TEG), which reflects high platelet-fibrin clot strength, and 1-year major adverse cardiovascular events (MACE) in patients who underwent isolated multi-vessel off-pump coronary artery bypass surgery (OPCAB). Patients and Methods: Data from 657 patients were retrospectively analyzed. TEG was performed post-anesthesia induction. MACE was defined as cardiovascular death, repeat revascularization, myocardial infarction, stroke, or rehospitalization due to heart failure. Patients were analyzed by tertiles of MA (mm). Logistic regression analyzed the association between 1-year MACE and MA. Results: The incidence of MACE increased with MA tertiles (1st: [<65.0]: 4.6%; 2nd [65.0–70.3]: 9.3%; 3rd [≥70.3]: 13%; p = 0.013). Logistic regression adjusted for known risk factors for MACE revealed an increased risk of MACE with higher MA tertiles (odds ratio [OR]: 1.99 [95% confidence interval {CI}: 0.92–4.55], p = 0.089 for the 2nd tertile; OR 2.78 [95% CI: 1.32–6.28], p = 0.010 for the 3rd tertile). A restricted cubic spline model revealed a linear relationship between MA and 1-year MACE. A 10-mm increase in MA was associated with a two-fold increase in the risk of 1-year MACE. The optimal MA cutoff for predicting MACE was 69.6 (normal range: 50.6–69.4). Conclusions: Increased thrombogenicity, reflected by elevated MA values, was linearly associated with the occurrence of 1-year MACE, highlighting the need for TEG screening and more aggressive, individualized perioperative anticoagulation management in selected patients with increased MA requiring OPCAB.
KW - Thromboelastography
KW - anticoagulation management
KW - dual antiplatelet therapy
KW - ischemic outcome
KW - major adverse cardiovascular events
KW - off-pump coronary artery bypass surgery
UR - https://www.scopus.com/pages/publications/105007840924
UR - https://www.scopus.com/inward/citedby.url?scp=105007840924&partnerID=8YFLogxK
U2 - 10.1080/07853890.2025.2514079
DO - 10.1080/07853890.2025.2514079
M3 - Article
C2 - 40492398
AN - SCOPUS:105007840924
SN - 0785-3890
VL - 57
JO - Annals of Medicine
JF - Annals of Medicine
IS - 1
M1 - 2514079
ER -